Washington, DC-MD-VA-WV – The availability of a new topical antibiotic formulation, known as TETRA-ABC, was announced this week at the national OSDBU Procurement Conference in Chantilly, Virginia. The development of this new drug formulation began in 2008 by Phillips Company, an FDA-registered Native American owned pharmaceutical manufacturer located in Oklahoma.
The manufacturer believes this is the world’s strongest broad-spectrum topical antibiotic. It kills the most drug-resistant and the most deadly bacteria (Staph, MRSA and Acinetobacter), which cause community or hospital acquired infections. The TETRA-ABC topical antibiotic kills all other Gram positive and Gram negative bacteria that have been available for testing.
The new antibiotic formulation is based on Tetracycline, the world’s most-used broad-spectrum antibiotic, according to Steve Keough, spokesman for Phillips Company. In-vitro tests, in controlled laboratory conditions, have shown that the Zone of Inhibition or kill zone is significantly larger than the area where the product is applied. Keough further added, “TETRA-ABC topical antibiotic is clearly a best in class pharmaceutical solution, with applications across multiple fields of use.”
Licensing, development and procurement inquiries: toll free phone 1-888-396-5139 or fax 1-866-542-5773.